RCS - Creo Medical Group - Royal Oldham SSD service update

Creo MedicalAnnouncement

16/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230816:nRSP4070Ja&default-theme=true

RNS Number : 4070J  Creo Medical Group PLC  16 August 2023

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Royal Oldham SSD service going from strength to strength

40 cases completed in record time, with patients and waiting lists
experiencing immediate benefits

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of minimally invasive surgical endoscopy, provides an update on
the implementation of its technology within The Royal Oldham Hospital ("Royal
Oldham"). On 17 May, Creo announced
(https://otp.tools.investis.com/clients/uk/creo_medical1/rns/regulatory-story.aspx?cid=2071&newsid=1688168)
that Royal Oldham had become the first NHS hospital to immediately implement
CROMA and Speedboat™ Inject across multiple endoscopy rooms, putting in
place weekly lists for multiple SSD (Speedboat Submucosal Dissection) cases.

 

The hospital has now treated over 40 patients using the new service,
representing the fastest time for any NHS hospital to reach the landmark, with
exceptional results for patients, the hospital and its staff. Multiple doctors
at the hospital have already progressed through Creo's Pioneer Programme
mentoring stage and are independently treating regular lists of patients
presenting with complex, high-risk lesions in the colon.

 

Creo has a target base for the Speedboat range of products of more than 350
NHS hospitals, with each SSD procedure demonstrated to save the NHS up to
£10k
(https://otp.tools.investis.com/clients/uk/creo_medical1/rns/regulatory-story.aspx?cid=2071&newsid=1478843)
when compared to traditional surgery, alongside a typically far shorter
hospital stay and significantly lower risk of complications. There are 23 NHS
England healthcare settings that have now adopted SSD.

 

Dr Sal Khalid, Consultant Gastroenterologist at the Royal Oldham Hospital,
said: "I'm very pleased with the outcomes the Speedboat Inject device is
facilitating for our patients, allowing our advanced endoscopists to remove
complex high-risk lesions and even early cancer without the patient requiring
invasive surgical treatment.

 

"Almost all bowel cancers start as a lesion, and so having the technology now
available to us to cut deeper and more safely through the layers of the bowel
when removing a lesion enables us to ensure that it's completely removed and
reduce the chances of patients requiring an operation.

 

"It's already clear that this will have a lasting effect, with the treatment
reducing the chances of recurrence from 15% to 1% and potentially providing a
cure for lesions containing early cancer without requiring operation.

 

"Indeed, only three months into the new service we are already recording a
reduction in the waiting lists not only across our endoscopy suites but,
perhaps most importantly, in terms of those waiting for the surgical treatment
of more invasive cancers.

 

"The best part about the new service is being able to call a patient a few
days later and tell them that they have had a curative outcome - that the
lesion has been removed with the necessary margins not to have to worry about
it anymore. That was rarely the case before we introduced Speedboat Inject and
the advanced energy.

 

"The establishment of this service will help us maintain our status as one of
the leading advanced endoscopy services in the country and help us move
towards our goal of prevention, early detection, and treatment of bowel
cancer."

 

Dr Khalid has now completed over 15 procedures using the Speedboat Inject
device. Out of the first 10 cases, two were confirmed as cancers and three as
showing features of high grade dysplasia, suggesting lesions very close to
turning into a cancer. All of these lesions were successfully removed
completely through an SSD procedure using Creo's advanced energy device.

 

What next?

·    SSD will become Royal Oldham's treatment of choice for high-risk
polyps suspected of containing early cancer. Hundreds of patients every year
are expected to benefit from this treatment option.

·     Royal Oldham plans to expand the service and increase the number of
conditions it can treat using this equipment. This will involve training
endoscopists to perform a wider array of procedures using CROMA and Speedboat.

·    An expanded service will be supported by a dedicated
multidisciplinary team involving experts from across all the relevant
specialties, ensuring every patient gets the best treatment based on expert
knowledge, with every decision supported by the most current medical evidence.

·     Royal Oldham will also aim to offer training opportunities to help
teach this advanced technique to a wider pool of doctors, including the
establishment of training posts of Endoscopy Fellows who will receive
dedicated training and experience of decision making and performing SSD
procedures under direct supervision of Dr Sal Khalid and his team.

 

Craig Gulliford, CEO of Creo Medical said: "Oldham provides a phenomenal model
for what's possible when a hospital immediately recognises the potential of
the device and implements the right pathways and resource to maximise its
impact.

 

"To know that there are 40 patients in and around Oldham who have already
benefited from our technology and the excellent service provided by Dr Khalid
and his team is incredibly gratifying, with the knock-on positive effects on
waiting lists and hospital resources now well established.

 

"To hear plans for the further expansion of the service is also excellent news
and we look forward to supporting the hospital in every way we can."

 

Enquiries:

 

 Creo Medical Group plc                             www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                 +44 (0)1291 606 005

 Cenkos Securities plc                              +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson (Sales)

 Numis Securities Limited (Joint Broker)            +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR                                        Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Sam Allen                           Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 Phillip Marriage                                   +44 (0)7867 984 082

 

 

About Creo Medical

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEALPSFALDEFA